On the contrary, no conclusive results have been achieved on the prognostic impact of CD4+ TILs in NSCLC [80,88] and, among the CD4+ subsets, Th1 lymphocytes have been associated with improved survival, while Th2 lymphocytes have been associated with tumor progression [89,90]. Here, CD4 is linked to non-small cell lung carcinoma.